Less than a week after Bayer announced plans to carve down its internal R&D group, laying off 900 R&D staffers, the German company has tipped the market that one of its crucial late-stage development efforts has run into serious trouble.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,